Navigation Links
Pixel Bridge Works With Anika Therapeutics to Launch New Website
Date:8/20/2008

Pixel Bridge, a Boston-based interactive marketing and Web development firm recently announced the launch of a new website for Anika Therapeutics - www.anikatherapeutics.com. Anika Therapeutics (NASDAQ: ANIK) develops products that address the fast-growing joint health, aesthetic, ophthalmic, veterinary and anti-adhesion markets. The company worked with Pixel Bridge to plan, design, develop and implement the new site.

Boston, MA (PRWEB) August 20, 2008 -- Pixel Bridge, a Boston-based interactive marketing and Web development firm recently announced the launch of a new website for Anika Therapeutics - www.anikatherapeutics.com. Anika Therapeutics (NASDAQ: ANIK) develops products that address the fast-growing joint health, aesthetic, ophthalmic, veterinary and anti-adhesion markets. The company worked with Pixel Bridge to plan, design, develop and implement the new site.

For more than 20 years, Anika has been a leader in developing therapies that leverage the benefits of hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body that enhances joint function and coats, protects, cushions and lubricates soft tissues. The company is recognized worldwide as a provider of premium HA products that are effective, safe and long-lasting.

The company's new interactive property is version 2.0 of the site. The key underlying goals associated with the project were to:

  • Effectively educate site visitors about the company's products

  • Visually represent Anika as an innovative leader in its markets

  • Clearly articulate the company's value proposition and market differentiation

"Our goal in designing this site was to capture the energy and entrepreneurial spirit of the company, along with its long history of leadership in therapeutic technologies," said Scott Stephens, president of Pixel Bridge. "Anika has a broad range of therapies in the market and an impressive pipeline of innovative products under development. This demanded a site that was both comprehensive and easy to navigate and reflective of the company's vision for the future. The new website illustrates the company's uniqueness and we were proud to work with them on the project."

"Pixel Bridge worked with us on every step of this engagement - from concept to completion," notes Kevin Quinlan, CFO and Treasurer at Anika. "The firm's full range of capabilities made a potentially cumbersome project streamlined and relatively painless."

ABOUT ANIKA THERAPEUTICS
Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika's products include ORTHOVISC(R), a treatment for osteoarthritis of the knee available internationally and marketed in the U.S. by DePuy Mitek; HYVISC(R), a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc.; the ELEVESS(TM) family of aesthetic dermatology products for facial wrinkles, scar remediation and lip augmentation marketed in the U.S. by Artes Medical, Inc.; AMVISC(R), AMVISC(R) Plus, STAARVISC(TM)-II and Shellgel(TM) injectable viscoelastic HA products for ophthalmic surgery; INCERT(R), an HA-based anti-adhesive for surgical applications; ORTHOVISC(R) mini a treatment for osteoarthritis targeting small joints and available in Europe; MONOVISC(TM) a single-injection osteoarthritis product based on our proprietary cross-linking technology and also available in Europe; and next generation products for joint health and aesthetic dermatology based on the Company's proprietary, chemically modified HA. For more information contact Anika at 781-457-9000 or visit www.anikatherapeutics.com.

ABOUT PIXEL BRIDGE
Pixel Bridge is a Boston-based interactive marketing and Web development firm that helps clients use the Internet to improve marketing, sales, and operations. Founded in 1999, the company seamlessly blends strategy, marketing, creative, and technology expertise to deliver highly effective websites, interactive marketing programs, and custom Internet applications. Pixel Bridge's client roster includes leading Boston-based companies such as The Boston Globe, Constant Contact, and Mac-Gray Corporation, as well as internationally recognized brands including Comcast, ITW, Krups, and Thomson. For more information contact Pixel Bridge at 617-542-5587 or visit www.pixelbridge.com.

Contacts
Pixel Bridge
Erin LaSpina
Tel: 617-542-5587
elaspina @ pixelbridge.com

2008 Pixel Bridge Inc, All Rights Reserved

###

Read the full story at http://www.prweb.com/releases/anikatherapeutics/newwebsite/prweb1226734.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. Siemens and Xintek Form Joint Venture to Develop Nanotechnology-Enabled Multi-Pixel X-ray Tubes
2. WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing
3. New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)
4. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
5. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
6. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
7. NIST team proves bridge from conventional to molecular electronics possible
8. Antibody Engineering Company f-Star Opens Second Research Site in Cambridge, UK
9. Woodbridge Offers the Broadest Range of BioFoam(TM) Green Polyurethane Automotive Interior Applications
10. Cambridge Major Appoints Professor John Hartwig as Scientific Advisor
11. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)...  If only one in every hundred cells ... to chemotherapy, thousands of cancer cells would remain ... finding these mutations in ever-smaller subpopulations of tumor ... in blood — to guide treatment decisions and ... however, detecting these genetic anomalies may be more ...
(Date:2/16/2017)... ... ... EIT Digital has launched work to develop a new Smart IOT ... to get under way for the framework, which is designed to reduce the use ... to be transferred eventually to other industries that also require efficient IoT and management ...
(Date:2/16/2017)... and GREENWICH, Conn. , ... investment firm focused on venture growth investments in ... of Josh Richardson , M.D. to Managing ... in biotechnology companies.  He is a board observer ... roles in Longitude,s investments in Aimmune Therapeutics, Akebia ...
(Date:2/16/2017)... Feb. 16, 2017 Research and ... Biology: Global Markets" report to their offering. ... ... genes, biobrick parts, delivery plasmids, chassis organisms, synthetic cells, ... assembly, genome editing, bioinformatics and specialty media) and enabled ...
Breaking Biology Technology:
(Date:2/8/2017)... LONDON , Feb. 7, 2017 Report ... $12.5 billion by 2021 from $8.3 billion in 2016 ... from 2016 to 2021. Report Includes - An ... of global market trends, with data from 2015 and ... through 2021. - Segmentation of the market on the ...
(Date:2/3/2017)... ANTONIO , Feb. 3, 2017  Texas Biomedical Research ... Dr. Larry Schlesinger as the Institute,s new ... Texas Biomed effective May 31, 2017. He is currently the ... Director of the Center for Microbial Interface Biology at Ohio ... Schlesinger as the new President and CEO of Texas Biomed," ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent market research, business ... new report, Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027 ... ... Revenues of ... for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine vision, force sensing ...
Breaking Biology News(10 mins):